{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:33:11Z","timestamp":1788874391363,"version":"build-2803163510"},"reference-count":101,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1053\/j.ajkd.2020.04.017","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T02:42:36Z","timestamp":1595472156000},"page":"110-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Resistant Hypertension in People With CKD: A Review"],"prefix":"10.1053","volume":"77","author":[{"given":"Kevin S.","family":"Fay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie L.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.ajkd.2020.04.017_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2016.19043","article-title":"Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015","volume":"317","author":"Forouzanfar","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"10.1053\/j.ajkd.2020.04.017_bib2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJMra1201534","article-title":"Measuring the global burden of disease","volume":"369","author":"Murray","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10100","key":"10.1053\/j.ajkd.2020.04.017_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(17)32366-8","article-title":"Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Gakidou","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.ajkd.2020.04.017_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","article-title":"Global disparities of hypertension prevalence and control","volume":"134","author":"Mills","year":"2016","journal-title":"Circulation"},{"issue":"5","key":"10.1053\/j.ajkd.2020.04.017_bib5","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"issue":"8","key":"10.1053\/j.ajkd.2020.04.017_bib6","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/jch.12773","article-title":"Blood pressure control provides less cardiovascular protection in adults with than without apparent treatment-resistant hypertension","volume":"18","author":"Egan","year":"2016","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"issue":"6","key":"10.1053\/j.ajkd.2020.04.017_bib7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jash.2014.03.003","article-title":"Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality","volume":"8","author":"Irvin","year":"2014","journal-title":"J\u00a0Am Soc Hypertens"},{"issue":"9","key":"10.1053\/j.ajkd.2020.04.017_bib8","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2215\/CJN.00550113","article-title":"Prevalence of apparent treatment-resistant hypertension among individuals with CKD","volume":"8","author":"Tanner","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2020.04.017_bib9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1681\/ASN.2015030243","article-title":"Masked uncontrolled hypertension in CKD","volume":"27","author":"Agarwal","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2020.04.017_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11886-019-1154-4","article-title":"Masked hypertension in CKD: increased prevalence and risk for cardiovascular and renal events","volume":"21","author":"Babu","year":"2019","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"10.1053\/j.ajkd.2020.04.017_bib11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.115.06487","article-title":"Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the Chronic Renal Insufficiency Cohort Study","volume":"67","author":"Thomas","year":"2016","journal-title":"Hypertension"},{"issue":"3","key":"10.1053\/j.ajkd.2020.04.017_bib12","doi-asserted-by":"crossref","first-page":"524","DOI":"10.2215\/CJN.06180616","article-title":"Recognition and management of resistant hypertension","volume":"12","author":"Braam","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2020.04.017_bib13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/jhh.2013.140","article-title":"Apparent and true resistant hypertension: definition, prevalence and outcomes","volume":"28","author":"Judd","year":"2014","journal-title":"J\u00a0Hum Hypertens"},{"issue":"6","key":"10.1053\/j.ajkd.2020.04.017_bib14","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"13","key":"10.1053\/j.ajkd.2020.04.017_bib15","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"issue":"3","key":"10.1053\/j.ajkd.2020.04.017_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ajh\/hpu151","article-title":"Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations","volume":"28","author":"Achelrod","year":"2015","journal-title":"Am J Hypertens"},{"issue":"5","key":"10.1053\/j.ajkd.2020.04.017_bib17","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring","volume":"57","author":"de la Sierra","year":"2011","journal-title":"Hypertension"},{"issue":"2","key":"10.1053\/j.ajkd.2020.04.017_bib18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1161\/HYPERTENSIONAHA.113.00687","article-title":"Measuring, analyzing, and managing drug adherence in resistant hypertension","volume":"62","author":"Burnier","year":"2013","journal-title":"Hypertension"},{"issue":"11","key":"10.1053\/j.ajkd.2020.04.017_bib19","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/heartjnl-2013-305063","article-title":"High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS\/MS) urine analysis","volume":"100","author":"Tomaszewski","year":"2014","journal-title":"Heart"},{"issue":"10","key":"10.1053\/j.ajkd.2020.04.017_bib20","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jamainternmed.2019.1455","article-title":"Use of directly observed therapy to assess treatment adherence in patients with apparent treatment-resistant hypertension","volume":"179","author":"Ruzicka","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1053\/j.ajkd.2020.04.017_bib21","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1161\/HYPERTENSIONAHA.119.14137","article-title":"Antihypertensive medication adherence and confirmation of true refractory hypertension","volume":"75","author":"Siddiqui","year":"2019","journal-title":"Hypertension"},{"issue":"6","key":"10.1053\/j.ajkd.2020.04.017_bib22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","article-title":"Original papers. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"4","author":"Cushman","year":"2002","journal-title":"J\u00a0Clin Hypertens"},{"issue":"3","key":"10.1053\/j.ajkd.2020.04.017_bib23","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2015.142","article-title":"Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension","volume":"88","author":"Sim","year":"2015","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2020.04.017_bib24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jash.2016.03.186","article-title":"Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement","volume":"10","author":"Bhatt","year":"2016","journal-title":"J\u00a0Am Soc Hypertens"},{"issue":"7","key":"10.1053\/j.ajkd.2020.04.017_bib25","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension","volume":"31","author":"Mancia","year":"2013","journal-title":"J\u00a0Hypertens"},{"issue":"5","key":"10.1053\/j.ajkd.2020.04.017_bib26","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1161\/01.CIR.0000154900.76284.F6","volume":"111","author":"Pickering","year":"2005","journal-title":"Circulation"},{"issue":"11","key":"10.1053\/j.ajkd.2020.04.017_bib27","doi-asserted-by":"crossref","first-page":"ITC1","DOI":"10.7326\/0003-4819-161-11-201412020-01006","article-title":"In thCclinic: hypertension","volume":"161","author":"Weir","year":"2014","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1053\/j.ajkd.2020.04.017_bib28","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0895-7061(01)02193-8","article-title":"Is resistant hypertension really resistant?","volume":"14","author":"Brown","year":"2001","journal-title":"Am J Hypertens"},{"issue":"21","key":"10.1053\/j.ajkd.2020.04.017_bib29","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/archinte.168.21.2340","article-title":"Prognostic influence of office and ambulatory blood pressures in resistant hypertension","volume":"168","author":"Salles","year":"2008","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1053\/j.ajkd.2020.04.017_bib30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/ajh.2007.43","article-title":"Factors influencing white-coat effect","volume":"21","author":"Manios","year":"2008","journal-title":"Am J Hypertens"},{"issue":"3","key":"10.1053\/j.ajkd.2020.04.017_bib31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.TP.0000435704.55805.f9","article-title":"Home blood pressure monitoring in heart transplant recipients: comparison with ambulatory blood pressure monitoring","volume":"97","author":"Ambrosi","year":"2014","journal-title":"Transplantation"},{"issue":"3","key":"10.1053\/j.ajkd.2020.04.017_bib32","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1053\/j.ajkd.2019.08.030","article-title":"Blood pressure measurement: a KDOQI perspective","volume":"75","author":"Drawz","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2020.04.017_bib33","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1161\/HYP.0000000000000087","article-title":"Measurement of blood pressure in humans: a scientific statement from the American Heart Association","volume":"73","author":"Muntner","year":"2019","journal-title":"Hypertension"},{"issue":"5","key":"10.1053\/j.ajkd.2020.04.017_bib34","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2020.04.017_bib35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jval.2013.03.1631","article-title":"Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR medication adherence and persistence special interest group","volume":"16","author":"Gwadry-Sridhar","year":"2013","journal-title":"Value Health"},{"issue":"5","key":"10.1053\/j.ajkd.2020.04.017_bib36","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2165\/00003088-199732050-00001","article-title":"The electronic medication event monitor. Lessons for pharmacotherapy","volume":"32","author":"Urquhart","year":"1997","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1053\/j.ajkd.2020.04.017_bib37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/jch.12896","article-title":"True resistant hypertension following observed drug ingestion: a systematic evaluation","volume":"19","author":"Bunker","year":"2017","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"issue":"6","key":"10.1053\/j.ajkd.2020.04.017_bib38","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000321688","article-title":"Adherence to antihypertensive agents and blood pressure control in chronic kidney disease","volume":"32","author":"Schmitt","year":"2010","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2020.04.017_bib39","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/1472-6963-12-270","article-title":"Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss","volume":"12","author":"Meddings","year":"2012","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1053\/j.ajkd.2020.04.017_bib40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0895-4356(96)00268-5","article-title":"The assessment of refill compliance using pharmacy records: methods, validity, and applications","volume":"50","author":"Steiner","year":"1997","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"11","key":"10.1053\/j.ajkd.2020.04.017_bib41","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1097\/00005650-199711000-00008","article-title":"Assessing compliance to antihypertensive medications using computer-based pharmacy records","volume":"35","author":"Christensen","year":"1997","journal-title":"Med Care"},{"issue":"1","key":"10.1053\/j.ajkd.2020.04.017_bib42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7326\/M14-2427","article-title":"Improving adherence to therapy and clinical outcomes while containing costs: opportunities from the greater use of generic medications: best practice advice from the Clinical Guidelines Committee of the American College of Physicians","volume":"164","author":"Choudhry","year":"2016","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1053\/j.ajkd.2020.04.017_bib43","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","article-title":"Fixed-dose combinations improve medication compliance: a meta-analysis","volume":"120","author":"Bangalore","year":"2007","journal-title":"Am J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2020.04.017_bib44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/HYPERTENSIONAHA.109.139816","article-title":"Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis","volume":"55","author":"Gupta","year":"2010","journal-title":"Hypertension"},{"issue":"4","key":"10.1053\/j.ajkd.2020.04.017_bib45","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s10865-010-9304-6","article-title":"Patient centered primary care is associated with patient hypertension medication adherence","volume":"34","author":"Roumie","year":"2011","journal-title":"J\u00a0Behav Med"},{"issue":"6","key":"10.1053\/j.ajkd.2020.04.017_bib46","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jama.2018.10359","article-title":"Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial","volume":"320","author":"Webster","year":"2018","journal-title":"JAMA"},{"issue":"3","key":"10.1053\/j.ajkd.2020.04.017_bib47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0197-2456(96)00235-8","article-title":"Comparing compliance patterns between randomized treatments","volume":"18","author":"Vrijens","year":"1997","journal-title":"Control Clin Trials"},{"issue":"5","key":"10.1053\/j.ajkd.2020.04.017_bib48","doi-asserted-by":"crossref","first-page":"I16","DOI":"10.1007\/BF03404494","article-title":"Adherence to pharmacologic management of hypertension","volume":"89","author":"Feldman","year":"1998","journal-title":"Can J Public Health"},{"key":"10.1053\/j.ajkd.2020.04.017_bib49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejphar.2015.06.027","article-title":"Drug induced hypertension \u2013 an unappreciated cause of secondary hypertension","volume":"763","author":"Grossman","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"10.1053\/j.ajkd.2020.04.017_bib50","first-page":"e2978","article-title":"Malignant hypertension in association with low estrogen dose oral contraceptives: case report and review of literature","volume":"10","author":"Mir","year":"2018","journal-title":"Cureus"},{"issue":"2","key":"10.1053\/j.ajkd.2020.04.017_bib51","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1378\/chest.06-1442","article-title":"Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension","volume":"131","author":"Pratt-Ubunama","year":"2007","journal-title":"Chest"},{"issue":"5","key":"10.1053\/j.ajkd.2020.04.017_bib52","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/ALN.0b013e31816d83e4","article-title":"STOP questionnaire: a tool to screen patients for obstructive sleep apnea","volume":"108","author":"Chung","year":"2008","journal-title":"Anesthesiology"},{"issue":"22","key":"10.1053\/j.ajkd.2020.04.017_bib53","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2013.281250","article-title":"Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial","volume":"310","author":"Martinez-Garcia","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"10.1053\/j.ajkd.2020.04.017_bib54","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1038\/sj.ki.5000307","article-title":"Determinants of baroreflex function in juvenile end-stage renal disease","volume":"69","author":"Studinger","year":"2006","journal-title":"Kidney Int"},{"issue":"5 suppl 1","key":"10.1053\/j.ajkd.2020.04.017_bib55","first-page":"S1","article-title":"Kidney Disease Outcomes Quality Initiative (K\/DOQI). K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2020.04.017_bib56","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1681\/ASN.2013030285","article-title":"A\u00a0randomized trial of dietary sodium restriction in CKD","volume":"24","author":"McMahon","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2020.04.017_bib57","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.109.131235","article-title":"Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial","volume":"54","author":"Pimenta","year":"2009","journal-title":"Hypertension"},{"issue":"4","key":"10.1053\/j.ajkd.2020.04.017_bib58","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/14656566.2014.879118","article-title":"Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics","volume":"15","author":"Tamargo","year":"2014","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1053\/j.ajkd.2020.04.017_bib59","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000358603","article-title":"Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study","volume":"39","author":"Agarwal","year":"2014","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2020.04.017_bib60","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.113.02793","article-title":"Parallel-group 8-week study on chlorthalidone effects in hypertensives with low kidney function","volume":"63","author":"Cirillo","year":"2014","journal-title":"Hypertension"},{"issue":"5","key":"10.1053\/j.ajkd.2020.04.017_bib61","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1517\/14656566.2014.879117","article-title":"Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents","volume":"15","author":"Tamargo","year":"2014","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"10.1053\/j.ajkd.2020.04.017_bib62","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1097\/HJH.0b013e3283551e98","article-title":"Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study","volume":"30","author":"Bobrie","year":"2012","journal-title":"J\u00a0Hypertens"},{"issue":"5","key":"10.1053\/j.ajkd.2020.04.017_bib63","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J\u00a0Clin Endocrinil Metab"},{"issue":"2","key":"10.1053\/j.ajkd.2020.04.017_bib64","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renal damage in primary aldosteronism: results of the PAPY Study","volume":"48","author":"Rossi","year":"2006","journal-title":"Hypertension"},{"issue":"7","key":"10.1053\/j.ajkd.2020.04.017_bib65","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/ajh.2009.63","article-title":"Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial","volume":"22","author":"Egan","year":"2009","journal-title":"Am J Hypertens"},{"issue":"11","key":"10.1053\/j.ajkd.2020.04.017_bib66","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/ajh.2011.171","article-title":"The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure","volume":"24","author":"Laragh","year":"2011","journal-title":"Am J Hypertens"},{"issue":"1","key":"10.1053\/j.ajkd.2020.04.017_bib67","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1053\/j.ajkd.2020.04.017_bib68","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension"},{"issue":"2","key":"10.1053\/j.ajkd.2020.04.017_bib69","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ajh\/hpx154","article-title":"Current concepts in the treatment of renovascular hypertension","volume":"31","author":"Herrmann","year":"2018","journal-title":"Am J Hypertens"},{"issue":"7","key":"10.1053\/j.ajkd.2020.04.017_bib70","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/HJH.0000000000000213","article-title":"European consensus on the diagnosis and management of fibromuscular dysplasia","volume":"32","author":"Persu","year":"2014","journal-title":"J\u00a0Hypertens"},{"issue":"4","key":"10.1053\/j.ajkd.2020.04.017_bib71","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.amjcard.2013.10.046","article-title":"Prevalence of and risk factors of renal artery stenosis in patients with resistant hypertension","volume":"113","author":"Benjamin","year":"2014","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1053\/j.ajkd.2020.04.017_bib72","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1310753","article-title":"Stenting and medical therapy for atherosclerotic renal-artery stenosis","volume":"370","author":"Cooper","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2020.04.017_bib73","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-150-12-200906160-00119","article-title":"Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial","volume":"150","author":"Bax","year":"2009","journal-title":"Ann Intern Med"},{"issue":"20","key":"10.1053\/j.ajkd.2020.04.017_bib74","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa0905368","article-title":"Revascularization versus medical therapy for renal-artery stenosis","volume":"361","author":"Wheatley","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1053\/j.ajkd.2020.04.017_bib75","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/CIRCULATIONAHA.106.174526","volume":"113","author":"Hirsch","year":"2006","journal-title":"Circulation"},{"issue":"6","key":"10.1053\/j.ajkd.2020.04.017_bib76","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1053\/j.ajkd.2018.06.018","article-title":"Optimized reference intervals for plasma free metanephrines in patients with CKD","volume":"72","author":"Pamporaki","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2020.04.017_bib77","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10043","key":"10.1053\/j.ajkd.2020.04.017_bib78","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0140-6736(16)30467-6","article-title":"Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies","volume":"388","author":"Mente","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.ajkd.2020.04.017_bib79","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.ki.5001955","article-title":"Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease","volume":"71","author":"Bellizzi","year":"2007","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2020.04.017_bib80","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/ajh\/hpz090","article-title":"DASH diet and blood\u00a0pressure among black Americans with and without CKD:\u00a0the Jackson Heart Study","volume":"32","author":"Tyson","year":"2019","journal-title":"Am J Hypertens"},{"issue":"3","key":"10.1053\/j.ajkd.2020.04.017_bib81","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1161\/HYPERTENSIONAHA.112.197780","article-title":"Aerobic exercise reduces blood pressure in resistant hypertension","volume":"60","author":"Dimeo","year":"2012","journal-title":"Hypertension"},{"issue":"1","key":"10.1053\/j.ajkd.2020.04.017_bib82","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12049","article-title":"Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment","volume":"15","author":"Landsberg","year":"2013","journal-title":"J\u00a0Clin Hypertens"},{"issue":"11","key":"10.1053\/j.ajkd.2020.04.017_bib83","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.2018.7777","article-title":"Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"320","author":"LeBlanc","year":"2018","journal-title":"JAMA"},{"issue":"11","key":"10.1053\/j.ajkd.2020.04.017_bib84","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.117.032130","article-title":"Effects of bariatric surgery in obese patients with hypertension","volume":"137","author":"Schiavon","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1053\/j.ajkd.2020.04.017_bib85","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/HYPERTENSIONAHA.118.12290","article-title":"Effects of bariatric surgery versus medical therapy on the 24-hour ambulatory blood pressure and the prevalence of resistant hypertension","volume":"73","author":"Schiavon","year":"2019","journal-title":"Hypertension"},{"issue":"6","key":"10.1053\/j.ajkd.2020.04.017_bib86","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/HJH.0000000000000902","article-title":"The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements","volume":"34","author":"Satoh","year":"2016","journal-title":"J\u00a0Hypertens"},{"issue":"10008","key":"10.1053\/j.ajkd.2020.04.017_bib87","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2020.04.017_bib88","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"10208","key":"10.1053\/j.ajkd.2020.04.017_bib89","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.ajkd.2020.04.017_bib90","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2337\/dc18-2207","article-title":"Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide","volume":"42","author":"Georgianos","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1053\/j.ajkd.2020.04.017_bib91","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11906-019-0920-4","article-title":"Blood pressure lowering and sodium-glucose co-transporter 2 inhibitors (SGLT2is): more than osmotic diuresis","volume":"21","author":"Sternlicht","year":"2019","journal-title":"Curr Hypertens Rep"},{"issue":"24","key":"10.1053\/j.ajkd.2020.04.017_bib92","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1053\/j.ajkd.2020.04.017_bib93","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2020.04.017_bib94","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/MNH.0b013e32834db45d","article-title":"Sympathetic nervous system: role in hypertension and in chronic kidney disease","volume":"21","author":"Grassi","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"15","key":"10.1053\/j.ajkd.2020.04.017_bib95","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A\u00a0controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9981","key":"10.1053\/j.ajkd.2020.04.017_bib96","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/S0140-6736(14)61942-5","article-title":"Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial","volume":"385","author":"Azizi","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.ajkd.2020.04.017_bib97","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/HJH.0000000000000556","article-title":"Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension","volume":"33","author":"Ott","year":"2015","journal-title":"J\u00a0Hypertens"},{"issue":"10137","key":"10.1053\/j.ajkd.2020.04.017_bib98","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"Kandzari","year":"2018","journal-title":"Lancet"},{"issue":"22","key":"10.1053\/j.ajkd.2020.04.017_bib99","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1161\/CIRCULATIONAHA.119.040451","article-title":"Six-month results of treatment-blinded medication titration for hypertension control following randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO Trial","volume":"139","author":"Azizi","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1053\/j.ajkd.2020.04.017_bib100","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1161\/HYPERTENSIONAHA.117.09086","article-title":"Sustained reduction of blood pressure with baroreceptor activation therapy: results of the 6-year open follow-up","volume":"69","author":"de Leeuw","year":"2017","journal-title":"Hypertension"},{"issue":"10113","key":"10.1053\/j.ajkd.2020.04.017_bib101","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1016\/S0140-6736(17)32337-1","article-title":"Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study","volume":"390","author":"Spiering","year":"2017","journal-title":"Lancet"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638620308507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638620308507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:30:54Z","timestamp":1759462254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638620308507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0272638620308507"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2020.04.017","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistant Hypertension in People With CKD: A Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2020.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}